CClinicalTrials.gg
Active, not recruitingNCT03495232Updated Dec 18, 2025

Persona Cohort Nordic Multicenter Study

An observational study in Knee Arthropathy, sponsored by Zimmer Biomet. Active, not recruiting at 4 sites in 4 countries. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Sex
All
01

Study summary

In this project the investigators wish to:

Evaluate intra-operative and postop complications, longer term survivorship and patient reported outcome measures (PROMs) following primary total knee replacement using Persona Total Knee system.

This project is carried out as prospective cohort study. Recruitment of participants to this project is expected to begin in October 2016 or as soon as permission from the Regional Ethics Committee and the local Data Protection Agency is obtained as required. A total of 700 participants (including 155 participants from a randomized controlled trial (RCT) investigating the Persona and the Nexgen total knee systems, which is separately submitted to the ethics committee) are to be included at several centers in the nordic region. Recruitment is expected complete after a period of 1,5 years per site. The patient follow-up visits are expected to be completed 2 years after recruitment of the last participant. Survivorship will be collected until 10 years after the recruitment of the last participant.

Participants are seen on an outpatient basis at 3 months and 1 and 2 years postoperatively.

After the 2 year follow-up visit the patients recruited in the Scandinavian sites will be followed for survivorship through the National Knee Arthroplasty Registries at 5, 7 and 10 years postoperatively. Since France does not have a national registry, the French site will also perform 5 year follow-up visits.

Read the detailed description

The investigators will retain the subject data sources, case report forms (CRFs) and electronic-CRFs in accordance with local laws and regulations.

The enrollment is competitive between the participating centers. Project information and consent according to local requirements before surgery is completed.

Surgery is performed as described in the manufacturer's surgical technique. A senior surgeon dedicated to total knee arthroplasty surgery will perform all operations with an assistant.

Participants will receive standard pain treatment and rehabilitation until discharge.

02

Conditions studied

  • Knee Arthropathy

Browse trials for

Keywords

  • Total Knee Arthroplasty
  • Persona knee system
  • osteoarthrosis
  • Knee
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient planned for primary total knee arthroplasty (TKA) on orthopedic surgeons' waiting list may be asked and selected for the study.

Inclusion criteria

  • Clinical and radiological osteoarthritis of the knee set to receive a primary unilateral total knee replacement

Exclusion criteria

Exclusion Criteria:

  • Patients who are unwilling or unable to give consent, or to comply with the follow-up program.
  • Patients that meet any contraindications listed in the Instruction for Use
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Interventions

  • DeviceZimmer Biomet Persona total knee system

    Product manufactured by Zimmer Biomet used to replace the knee joint.

05

What researchers measure

Primary outcomes

  1. Evaluate patient reported outcome measures following primary total knee replacement using Persona Total Knee system

    Evaluate patient reported outcome measures following primary total knee replacement using Persona Total Knee system as measured by Oxford knee score (OKS); a 12-item patient-reported Patient Reported Outcomes specifically designed and developed to assess function and pain after total knee replacement surgery. Score ranging from 0 (most severe symptoms/problems) to 48 (least severe).

    Time frame: 2 years

Secondary outcomes

  1. Evaluate patient reported physical activity level following primary total knee replacement using Persona Total Knee system. An 8-item patient-reported outcome. Score ranging from 0 (most severe symptoms/problems) to 32 (least severe).

    Oxford knee score Activity \& Participation Questionnaire (OKS, APQ)

    Time frame: 2 years

  2. Evaluate patient quality of life following primary total knee replacement using Persona Total Knee system

    EuroQol Group (EQ5D) standardized measure of health status. Measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Overall health status rated by the patient using the visual analogue scale (EQ-VAS).

    Time frame: 2 years

  3. Evaluate patient satisfaction following primary total knee replacement using Persona Total Knee system

    Anchoring questions. Focusing on Patient perception of their knee and their satisfaction with the knee after their knee surgery

    Time frame: 2 years

  4. Evaluate patient reported awareness of their knee following primary total knee replacement using Persona Total Knee system

    Forgotten Joint Score (FJS)

    Time frame: 2 years

  5. Evaluate intraoperative and postoperative complications

    Register adverse events including intraoperative complications and revisions at any postoperative time point.

    Time frame: 10 years

  6. Evaluate implant positioning following primary total knee replacement using Persona Total Knee system

    Measure radiolucency and osteolysis using conventional radiographs in anterior posterior (AP) and lateral views.

    Time frame: 2 years

  7. Evaluate longer term survivorship following primary total knee replacement using Persona Total Knee system

    Survival of the implant through registries

    Time frame: 10 years

06

Study locations

4 sites
  • Copenhagen University Hospital, Hvidovre
    Copenhagen, Denmark
  • Institute Locomoteur de L'Ouest
    Saint-Grégoire, 35760, France
  • St Olavs Hospital
    Trondheim, Norway
  • Ortopedic Clinic, Motala Specialist Care Capio AB
    Motala, Sweden
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03495232
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Apr 11, 2018
Start date
Nov 1, 2016
Primary completion
Apr 7, 2029 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Dec 18, 2025

Study contacts

Anders Troelsen, Prof
principal investigator · Copenhagen University Hospital, Hvidovre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion